Interaction Checker
Potential Interaction
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
_ZZSaquinavir (SQV)
Quality of Evidence: Very Low
Summary:
Coadministration with emtricitabine/tenofovir-DF has not been studied. Saquinavir is primarily metabolised by CYP3A4 and based on metabolism and clearance a clinically significant interaction with emtricitabine is unlikely. The effect of tenofovir-DF (300 mg once daily) on saquinavir/ritonavir (1000/100 mg twice daily) was studied in 18 HIV+ subjects. There was no significant change at steady state in saquinavir AUC (1% decrease), Cmax (7% decrease) or Cmin (16% increase). When the same doses were studied in 35 HIV- subjects, tenofovir AUC and Cmax were unaltered and Cmin increased 23%; saquinavir AUC, Cmax, and Cmin increased by 29%, 22% and 47% respectively. No dose adjustment is required. However, a higher risk of renal impairment has been reported in patients receiving tenofovir-DF in combination with a ritonavir boosted protease inhibitor. Close monitoring of renal function is required in these patients.
Description:
View all available interactions with Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking here.
No Version Present
Copyright © 2024 The University of Liverpool. All rights reserved.